PARP1 and cancer: Beyond its well-documented contribution to cancer sustenance, PI3K signaling entangled association with chemoresistance mechanisms including drug-efflux proteins, cancer cell stemness, and regulation of PARP activity21, makes it a compelling target in TNBC which was underscored in numerous clinical trials9,22.